Learn how smoking cessation after a cancer diagnosis is associated with improved survival. Review effective approaches to screen patients for their smoking status, advise those who are current or recent users of tobacco of the health benefits of quitting, and facilitate access to evidence-based resources to help patients be free of tobacco.

These 10-12-minute recordings were presented at the 2023 World Conference on Lung Cancer.

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this activity, the participants should be able to:

• Develop up-to-date knowledge and competency in smoking cessation. 
• Recognize the critical importance of screening every patient for tobacco dependency.
• Incorporate smoking cessation as a standard part of cancer care.
• Integrate smoking cessation discussions with patients. 
• Advise patients who use tobacco of the health benefits of quitting.
• Facilitate access to evidence-based resources to help patients be free of tobacco.

Presenters:

• Matthew A. Steliga, MD, FACS, Professor of Surgery, Division Chief Thoracic Surgery, Tobacco Cessation Program, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, USA
• Magdalena Cedzynska, MS, Director, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
• Matthew Evison, MD, Consultant Chest Physician, Specialty Lead, Lung Cancer & Thoracic Surgery Directorate, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
• Henry Marshall, PhD, BsC, FRACP, The Prince Charles Hospital and University of Queensland, Brisbane, Australia

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need any assistance with this activity, please email: education@iaslc.org.